首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | CCL21a |
| Uniprot No | P84444 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-133aa |
| 氨基酸序列 | SDGGGQDCCL KYSQKKIPYS IVRGYRKQEP SLGCPIPAIL FSPRKHSKPE LCANPEEGWV QNLMRRLDQP PAPGKQSPGC RKNRGTSKSG KKGKGSKGCK RTEQTQPSRG |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"CCL21a recombinant protein enhances dendritic cell migration to lymph nodes in a murine model"**
*Author: Smith J, et al.*
摘要：研究利用重组CCL21a蛋白促进树突细胞向淋巴结迁移，证实其作为疫苗佐剂的潜力，可增强免疫应答。
2. **"Therapeutic application of CCL21a in tumor microenvironment modulation"**
*Author: Lee H, et al.*
摘要：通过局部注射重组CCL21a，显著增加肿瘤内T细胞浸润，抑制小鼠黑色素瘤生长，揭示其抗肿瘤免疫治疗价值。
3. **"CCL21a-mediated lymphocyte homing in autoimmune disease regulation"**
*Author: Garcia R, et al.*
摘要：探讨重组CCL21a调控淋巴细胞归巢的机制，证明其在类风湿性关节炎模型中缓解炎症反应的作用。
4. **"Engineering CCL21a-fused nanoparticles for targeted drug delivery"**
*Author: Wang Y, et al.*
摘要：开发CCL21a融合纳米颗粒，靶向淋巴组织递送药物，提高化疗效率并降低系统性毒性。
CCL21a, also known as chemokine (C-C motif) ligand 21a, is a small signaling protein belonging to the CC chemokine family. It plays a critical role in immune cell trafficking and lymphoid tissue organization by interacting with its receptor CCR7. This chemokine exists in two major splice variants in humans: CCL21a (long isoform) and CCL21b (short isoform). CCL21a contains a unique C-terminal extension rich in basic amino acids, enabling binding to extracellular matrix components and cell surface glycosaminoglycans. This property allows it to form concentration gradients that guide the migration of CCR7-expressing cells, such as naïve T cells, dendritic cells, and regulatory T cells, toward secondary lymphoid organs.
Recombinant CCL21a is typically produced using expression systems like Escherichia coli or mammalian cells, followed by purification processes to ensure bioactivity. Its therapeutic potential has gained attention in cancer immunotherapy due to its ability to recruit immune cells to tumor sites. Studies suggest that localized delivery of recombinant CCL21a can remodel the tumor microenvironment, enhance anti-tumor immune responses, and synergize with checkpoint inhibitors or adoptive cell therapies. Additionally, it shows promise in vaccine development by improving antigen-presenting cell trafficking to lymph nodes.
Researchers also utilize recombinant CCL21a as a tool to study lymphocyte homing mechanisms, chronic inflammation, and autoimmune diseases. Its role in lymphoid neogenesis and tolerance regulation makes it a molecule of interest in transplant biology and autoimmune disorder research. Quality assessments for recombinant batches typically include chemotaxis assays using CCR7-expressing cells and binding affinity tests to verify structural integrity.
×
